Ubs Group Ag Tg Therapeutics, Inc. Call Options Transaction History
Ubs Group Ag
- $555 Billion
- Q2 2025
Call Options
1 transactions
Others Institutions Holding TGTX
# of Institutions
406Shares Held
92.4MCall Options Held
2.28MPut Options Held
1.78M-
Vanguard Group Inc Valley Forge, PA15.8MShares$577 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$416 Million0.0% of portfolio
-
State Street Corp Boston, MA7.62MShares$278 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.49MShares$127 Million0.01% of portfolio
-
Clearbridge Investments, LLC New York, NY3.05MShares$111 Million0.09% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $5.3B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...